PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies

PEGylated nanomedicines are known to induce infusion reactions (IRs) that in some cases can be life-threatening. Herein, we report a case study in which a patient with rare mediastinal and intracardiac IgG4-related sclerosing disease received 8 treatments of intravenously administered PEGylated liposomal methylprednisolone-succinate (NSSL-MPS). Due to the ethical requirements to reduce IRs, the patient received a cocktail of premedication including low dose of steroids, acetaminophen and H2 blockers before each infusion. The treatment was well-tolerated in that IRs, complement activation, anti-PEG antibodies and accelerated blood clearance of the PEGylated drug were not detected. Prior to the clinical study, an in vitro panel of assays utilizing blood of healthy donors was used to determine the potential of a PEGylated drug to activate complement system, elicit pro-inflammatory cytokines, damage erythrocytes and affect various components of the blood coagulation system. The overall findings of the in vitro panel were negative and correlated with the results observed in the clinical phase.

[1]  Y. Barenholz,et al.  Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Effects of Liposomes , 2021, Handbook of Harnessing Biomaterials in Nanomedicine.

[2]  Yechezkel Barenholz,et al.  Roadmap and strategy for overcoming infusion reactions to nanomedicines , 2018, Nature Nanotechnology.

[3]  A. Cervantes,et al.  Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Yechezkel Barenholz,et al.  Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro , 2018, Molecules.

[5]  A. Kawashima,et al.  Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases , 2018, Heart and Vessels.

[6]  S. Fukui,et al.  Serum complement factor C5a in IgG4-related disease , 2018, Annals of the rheumatic diseases.

[7]  P. Gaillard,et al.  Glutathione‐PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first‐in‐human study , 2018, British journal of clinical pharmacology.

[8]  Y. Barenholz,et al.  Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance , 2018, ACS omega.

[9]  A. Cervantes,et al.  Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Stone,et al.  IgG4-related disease , 2017, Current opinion in rheumatology.

[11]  Dan Peer,et al.  Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. , 2017, ACS nano.

[12]  Yu-Cheng Su,et al.  Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. , 2016, Analytical chemistry.

[13]  Steve Y. Cho,et al.  Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. , 2016, ACS applied materials & interfaces.

[14]  Y. Barenholz,et al.  A liposomal steroid nano-drug for treating systemic lupus erythematosus , 2016, Lupus.

[15]  Jeffrey M. Sailstad,et al.  Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer , 2015, The Journal of allergy and clinical immunology.

[16]  R. Rodríguez‐Gutiérrez,et al.  Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. , 2015, World journal of diabetes.

[17]  Uri Raviv,et al.  Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases , 2015, PloS one.

[18]  J. Stone,et al.  IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients , 2015, Arthritis & rheumatology.

[19]  J. Stone,et al.  IgG4-related disease , 2015, The Lancet.

[20]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. , 2014, Molecular immunology.

[21]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[22]  M. Hershfield,et al.  Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients , 2014, Arthritis Research & Therapy.

[23]  Yechezkel Barenholz,et al.  Glucocorticosteroids in Nano-Sterically Stabilized Liposomes Are Efficacious for Elimination of the Acute Symptoms of Experimental Cerebral Malaria , 2013, PloS one.

[24]  E. Azzopardi,et al.  The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.

[25]  Vikram Deshpande,et al.  IgG4-Related Disease , 2013, International journal of rheumatology.

[26]  S. Moghimi,et al.  Complement sensing of nanoparticles and nanomedicines , 2012 .

[27]  T. Ishida,et al.  Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. , 2012, International journal of pharmaceutics.

[28]  A. Sigal,et al.  Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Yechezkel Barenholz,et al.  Fabrication Principles and Their Contribution to the Superior In Vivo Therapeutic Efficacy of Nano-Liposomes Remote Loaded with Glucocorticoids , 2011, PloS one.

[30]  Yechezkel Barenholz,et al.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.

[31]  K. Tsubota,et al.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details , 2011, Modern rheumatology.

[32]  K. Uchida,et al.  Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease , 2011, Journal of Gastroenterology.

[33]  T. Hirano,et al.  Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[34]  T. Cheng,et al.  Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. , 2010, Bioconjugate chemistry.

[35]  Hiroyuki Yamamoto,et al.  The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome--expansion of SIPS to the territory of Castleman's disease. , 2009, Rheumatology.

[36]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[37]  K. Tsubota,et al.  Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders , 2008, Annals of the rheumatic diseases.

[38]  Anil K Patri,et al.  Method for analysis of nanoparticle hemolytic properties in vitro. , 2008, Nano letters.

[39]  C. Chung.  Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. , 2008, The oncologist.

[40]  T. Ishida,et al.  Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. , 2008, International journal of pharmaceutics.

[41]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[42]  M. Hershfield,et al.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. , 2007, Arthritis and rheumatism.

[43]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  T. Ishida,et al.  Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[45]  S. Hsiao,et al.  Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. , 2005, Bioconjugate chemistry.

[46]  Frieder Keller,et al.  Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids , 2005, Clinical Pharmacokinetics.

[47]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  M. Wauben,et al.  Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.

[49]  B. Goins,et al.  Accumulation of PEG-liposomes in the Inflamed Colon of Rats: Potential for Therapeutic and Diagnostic Targeting of Inflammatory Bowel Diseases , 2002, Journal of drug targeting.

[50]  W. Oyen,et al.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.

[51]  S. Spitzauer,et al.  Complement Activation in SeverePlasmodium falciparumMalaria , 1997 .

[52]  C. Alving,et al.  Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1. , 1997, Artificial cells, blood substitutes, and immobilization biotechnology.

[53]  Dayan Ad.  Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .

[54]  C. Alving,et al.  Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. , 1994, Biochemical and biophysical research communications.

[55]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[56]  S. Abramson,et al.  Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. , 1992, Arthritis and rheumatism.

[57]  H. Rogers,et al.  Methylprednisolone pharmacokinetics after intravenous and oral administration. , 1989, British journal of clinical pharmacology.

[58]  F. Zijlstra,et al.  Raised plasma thromboxane B2 levels in alcoholic liver disease. , 1983, Prostaglandins, leukotrienes, and medicine.

[59]  J Pinkhas,et al.  Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis. , 1981, The American journal of medicine.

[60]  M. Dobrovolskaia,et al.  Analysis of Complement Activation by Nanoparticles. , 2018, Methods in molecular biology.

[61]  M. Dobrovolskaia,et al.  In Vitro Assessment of Nanoparticle Effects on Blood Coagulation. , 2018, Methods in molecular biology.

[62]  M. Dobrovolskaia,et al.  Updated Method for In Vitro Analysis of Nanoparticle Hemolytic Properties. , 2018, Methods in molecular biology.

[63]  M. Dobrovolskaia,et al.  Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles. , 2018, Methods in molecular biology.

[64]  J. Vikse,et al.  IgG 4-related disease , 2018 .

[65]  N. de Vries,et al.  [IgG4-related disease]. , 2013, Nederlands tijdschrift voor geneeskunde.

[66]  Hisanori UmeharaKazuichi.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details , 2012 .

[67]  Yechezkel Barenholz,et al.  Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. , 2008, Arthritis and rheumatism.

[68]  Yechezkel Barenholz,et al.  Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. , 2003, Methods in enzymology.

[69]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[70]  J. Cidlowski,et al.  Physiologic and Pharmacologic Effects of Corticosteroids , 2003 .

[71]  Y. Koyanagi,et al.  Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy , 1996 .

[72]  P. Working,et al.  Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996, Human & experimental toxicology.

[73]  E. Åkerblom,et al.  Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.